reatment Standards and Outcomes of Patients With ER/PR Positive HER2-negative Metastatic Breast Cancer

  • STATUS
    Recruiting
  • participants needed
    300
  • sponsor
    Hellenic Society of Medical Oncology
Send
Updated on 16 February 2024
See if I qualify
cancer
breast cancer
stage iv breast cancer
HER2

Summary

To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

Description

  • To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
    • To evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival
    • To record adverse events per line of therapy
    • To recording of the causes of treatment discontinuation per line of therapy

Details
Condition Metastatic Breast Cancer
Age 18years - 100years
Clinical Study IdentifierNCT04247035
SponsorHellenic Society of Medical Oncology
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Women with histological confirmed ER/PR positive, HER2-negative MBC
Age >18 years old
Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC
Adequate hematologic, renal and hepatic function
Signed informed consent (ICF)

Exclusion Criteria

Active malignancy other than MBC
Active infection
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
breast cancer
stage iv breast cancer
HER2

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.